Zenas BioPharma, Inc. Common Stock (ZBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Zenas BioPharma, Inc. Common Stock (ZBIO) has a cash flow conversion efficiency ratio of -0.216x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-52.41 Million) by net assets ($242.14 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Zenas BioPharma, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2022–2025)
This chart illustrates how Zenas BioPharma, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read ZBIO liabilities breakdown for a breakdown of total debt and financial obligations.
Zenas BioPharma, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Zenas BioPharma, Inc. Common Stock ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Polestar Automotive Holding UK PLC Class A ADS
NASDAQ:PSNY
|
0.058x |
|
Newag S.A.
WAR:NWG
|
0.241x |
|
Home First Finance Company India Limited
NSE:HOMEFIRST
|
-0.121x |
|
Delong Composite Energy Group Co Ltd
SHE:000593
|
0.009x |
|
ManpowerGroup Inc
NYSE:MAN
|
-0.051x |
|
Beijing China Sciences Runyu Environmental Technology Co. Ltd.
SHE:301175
|
0.034x |
|
Suburban Propane Partners LP
NYSE:SPH
|
-0.076x |
|
Hangzhou Zhongtai Cryogenic Technology Corp
SHE:300435
|
0.070x |
Annual Cash Flow Conversion Efficiency for Zenas BioPharma, Inc. Common Stock (2022–2025)
The table below shows the annual cash flow conversion efficiency of Zenas BioPharma, Inc. Common Stock from 2022 to 2025. For the full company profile with market capitalisation and key ratios, see ZBIO market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $242.14 Million | $-172.33 Million | -0.712x | -85.82% |
| 2024-12-31 | $312.46 Million | $-119.67 Million | -0.383x | -383.18% |
| 2023-12-31 | $-225.72 Million | $-30.53 Million | 0.135x | -60.39% |
| 2022-12-31 | $-192.29 Million | $-65.65 Million | 0.341x | -- |
About Zenas BioPharma, Inc. Common Stock
Zenas BioPharma, Inc., a clinical-stage biopharma company, engages in the development and commercialization of transformative immunology-based therapies. Its lead product candidate is obexelimab, a bifunctional monoclonal antibody designed to bind CD19 and Fc"RIIb for the treatment of various I&I diseases and various indications, including immunoglobulin G4-related disease, multiple sclerosis, an… Read more